Morgan Stanley and Leerink partners provided buy ratings and target prices for AgomAb Therapeutics on June 29, 2026.

The entities involved

• Morgan Stanley →

  U.S. investment bank

  • Bank of America and Morgan Stanley are restricting third-party AI agents amid cybersecurity scares and a declared bank run threat.13:24
  • Corning saw rating changes and price target adjustments from Morgan Stanley and Truist Financial, alongside increased shareholding by the Czech National Bank.11:07
• Leerink partners →

  U.S. investment bank

  • Summit seeks FDA approval for its drug, which was presented at the ASCO meeting. The company is developing ivonescimab with Akeso.12:46
  • Intuitive Surgical received a Buy rating from Leerink partners, citing increased da Vinci placements and potential benefits from Trump-era tariffs.Sat 07:31

Related events

• Leerink Partners increased its price target and Morgan Stanley reiterated an overweight rating for REGENXBIO Inc.Oct 8
• Leerink Partners and Barclays raised price targets on Elevance Health, while MarketBeat reported consensus ratings.Wed 15:16
• Leerink Partners, Truist Financial, HSBC, and Cantor Fitzgerald raised target prices on various stocks on October 9, 2026.Oct 10
• Citigroup, Morgan Stanley, and TD Cowen have raised their price targets and upgraded ratings for Royalty Pharma, with filings made public via the SEC.Jul 17
• Multiple financial institutions, including Morgan Stanley, Citigroup, and TD Cowen, boosted price targets and upgraded ratings on October 16, 2026.Oct 16